Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
: NHANES LBXGLU: Fasting Glucose (mg/dL) Variable Definition - TTL Representation
Raw ttl | Download
@prefix fhir: <http://hl7.org/fhir/> .
@prefix loinc: <https://loinc.org/rdf/> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
# - resource -------------------------------------------------------------------
a fhir:Group ;
fhir:nodeRole fhir:treeRoot ;
fhir:id [ fhir:v "282882"] ; #
fhir:meta [
fhir:versionId [ fhir:v "4" ] ;
fhir:lastUpdated [ fhir:v "2024-10-15T18:33:30.190Z"^^xsd:dateTime ]
] ; #
fhir:text [
fhir:status [ fhir:v "extensions" ] ;
fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: Group 282882</b></p><a name=\"282882\"> </a><a name=\"hc282882\"> </a><a name=\"282882-en-US\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">version: 4; Last updated: 2024-10-15 18:33:30+0000</p></div><p><b>Artifact Author</b>: Brian S. Alper: </p><p><b>Artifact related artifact</b>: No display for RelatedArtifact (type: cite-as; citation: NHANES LBXGLU: Fasting Glucose (mg/dL) Variable Definition [Database Entry: FHIR Group Resource]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 282882. Revised 2024-10-14. Available at: https://fevir.net/resources/Group/282882. Computable resource at: https://fevir.net/resources/Group/282882.)</p><p><b>url</b>: <a href=\"https://fevir.net/resources/Group/282882\">https://fevir.net/resources/Group/282882</a></p><p><b>identifier</b>: FEvIR Object Identifier/282882</p><p><b>title</b>: NHANES LBXGLU: Fasting Glucose (mg/dL) Variable Definition</p><p><b>status</b>: Active</p><p><b>publisher</b>: Computable Publishing LLC</p><p><b>contact</b>: <a href=\"mailto:support@computablepublishing.com\">support@computablepublishing.com</a></p><p><b>description</b>: </p><div><p>This Group Resource is referenced in an example for the EBMonFHIR Implementation Guide.</p>\n</div><p><b>copyright</b>: </p><div><p>https://creativecommons.org/licenses/by-nc-sa/4.0/</p>\n</div><p><b>membership</b>: Conceptual</p><p><b>combinationMethod</b>: All of</p><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title=\"Codes:\">Laboratory test</span></p><p><b>value</b>: <span title=\"Codes:{http://loinc.org 1558-6}\">Fasting plasma glucose</span></p><p><b>exclude</b>: false</p></blockquote><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title=\"Codes:\">Unit of measure</span></p><p><b>value</b>: <span title=\"Codes:\">mg/dL</span></p><p><b>exclude</b>: false</p></blockquote><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title=\"Codes:\">Method</span></p><p><b>value</b>: <span title=\"Codes:\">Description of Laboratory Methodology - Glucose - In this enzymatic method glucose is converted to glucose-6-phosphate (G-6-P) by hexokinase in the presence of ATP, a phosphate donor. Glucose-6-phosphate dehydrogenase then converts the G-6-P to gluconate-6-P in the presence of NADP+. As the NADP+ is reduced to NADPH during this reaction, the resulting increase in absorbance at 340 nm (secondary wavelength = 700 nm) is measured. This is an endpoint reaction that is specific for glucose. Refer to the Laboratory Method Files section for a detailed description of the laboratory methods used. There were no changes to the lab site or lab method for this component in the NHANES 2017-2018 cycle. There were no changes to the lab equipment since 2015-2016. The Cobas C311 analyzer was used in 2017-2018 and 2015-2016. Refer to analytic note for changes to equipment in earlier survey cycles, which may impact analysis. Plasma Fasting Glucose Laboratory Procedure Manual (August 2020) https://wwwn.cdc.gov/nchs/data/nhanes/2017-2018/labmethods/GLU-J-MET-508.pdf</span></p><p><b>exclude</b>: false</p></blockquote></div>"
] ; #
fhir:extension ( [
fhir:url [ fhir:v "http://hl7.org/fhir/StructureDefinition/artifact-author"^^xsd:anyURI ] ;
fhir:value [
a fhir:ContactDetail ;
fhir:name [ fhir:v "Brian S. Alper" ] ]
] [
fhir:url [ fhir:v "http://hl7.org/fhir/StructureDefinition/artifact-relatedArtifact"^^xsd:anyURI ] ;
fhir:value [
a fhir:RelatedArtifact ;
fhir:type [ fhir:v "cite-as" ] ;
fhir:citation [ fhir:v "NHANES LBXGLU: Fasting Glucose (mg/dL) Variable Definition [Database Entry: FHIR Group Resource]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 282882. Revised 2024-10-14. Available at: https://fevir.net/resources/Group/282882. Computable resource at: https://fevir.net/resources/Group/282882." ] ]
] ) ; #
fhir:url [ fhir:v "https://fevir.net/resources/Group/282882"^^xsd:anyURI] ; #
fhir:identifier ( [
fhir:type [
( fhir:coding [
fhir:system [ fhir:v "http://terminology.hl7.org/CodeSystem/v2-0203"^^xsd:anyURI ] ;
fhir:code [ fhir:v "ACSN" ] ;
fhir:display [ fhir:v "Accession ID" ] ] ) ;
fhir:text [ fhir:v "FEvIR Object Identifier" ] ] ;
fhir:system [ fhir:v "https://fevir.net"^^xsd:anyURI ] ;
fhir:value [ fhir:v "282882" ] ;
fhir:assigner [
fhir:display [ fhir:v "Computable Publishing LLC" ] ]
] ) ; #
fhir:title [ fhir:v "NHANES LBXGLU: Fasting Glucose (mg/dL) Variable Definition"] ; #
fhir:status [ fhir:v "active"] ; #
fhir:publisher [ fhir:v "Computable Publishing LLC"] ; #
fhir:contact ( [
( fhir:telecom [
fhir:system [ fhir:v "email" ] ;
fhir:value [ fhir:v "support@computablepublishing.com" ] ] )
] ) ; #
fhir:description [ fhir:v "This Group Resource is referenced in an example for the EBMonFHIR Implementation Guide."] ; #
fhir:copyright [ fhir:v "https://creativecommons.org/licenses/by-nc-sa/4.0/"] ; #
fhir:membership [ fhir:v "conceptual"] ; #
fhir:combinationMethod [ fhir:v "all-of"] ; #
fhir:characteristic ( [
fhir:code [
fhir:text [ fhir:v "Laboratory test" ] ] ;
fhir:value [
a fhir:CodeableConcept ;
( fhir:coding [
a loinc:1558-6 ;
fhir:system [ fhir:v "http://loinc.org"^^xsd:anyURI ] ;
fhir:code [ fhir:v "1558-6" ] ;
fhir:display [ fhir:v "Fasting glucose [Mass/volume] in Serum or Plasma" ] ] ) ;
fhir:text [ fhir:v "Fasting plasma glucose" ] ] ;
fhir:exclude [ fhir:v "false"^^xsd:boolean ]
] [
fhir:code [
fhir:text [ fhir:v "Unit of measure" ] ] ;
fhir:value [
a fhir:CodeableConcept ;
fhir:text [ fhir:v "mg/dL" ] ] ;
fhir:exclude [ fhir:v "false"^^xsd:boolean ]
] [
fhir:code [
fhir:text [ fhir:v "Method" ] ] ;
fhir:value [
a fhir:CodeableConcept ;
fhir:text [ fhir:v "Description of Laboratory Methodology - Glucose - In this enzymatic method glucose is converted to glucose-6-phosphate (G-6-P) by hexokinase in the presence of ATP, a phosphate donor. Glucose-6-phosphate dehydrogenase then converts the G-6-P to gluconate-6-P in the presence of NADP+. As the NADP+ is reduced to NADPH during this reaction, the resulting increase in absorbance at 340 nm (secondary wavelength = 700 nm) is measured. This is an endpoint reaction that is specific for glucose. Refer to the Laboratory Method Files section for a detailed description of the laboratory methods used. There were no changes to the lab site or lab method for this component in the NHANES 2017-2018 cycle. There were no changes to the lab equipment since 2015-2016. The Cobas C311 analyzer was used in 2017-2018 and 2015-2016. Refer to analytic note for changes to equipment in earlier survey cycles, which may impact analysis. Plasma Fasting Glucose Laboratory Procedure Manual (August 2020) https://wwwn.cdc.gov/nchs/data/nhanes/2017-2018/labmethods/GLU-J-MET-508.pdf" ] ] ;
fhir:exclude [ fhir:v "false"^^xsd:boolean ]
] ) . #
|
Propose a change